Labcorp to spin off clinical development business

Burlington, n.c.--(business wire)--labcorp (nyse: lh) (the “company”), a leading global life sciences company, today announced that its board of directors has authorized the company to pursue a spin-off of the company's wholly owned clinical development business to labcorp shareholders through a tax-free transaction. the planned spin-off will result in two independent, publicly traded companies, each poised for strong, sustainable growth: labcorp: a leading global laboratory business comprising
LH Ratings Summary
LH Quant Ranking